COPENHAGEN (Reuters) – Novo Nordisk does not expect a shortage of its Wegovy weight-loss drug in Denmark despite an earlier warning by the Danish Medicines Agency of strained supply of two separate doses in the coming weeks, the company said.
The Danish regulator on Monday issued two statements saying the country faced a shortage of the Wegovy Flextouch 1 mg injection pen from late May to mid-June and the 0.5 mg Wegovy Flextouch injection pen between mid-June and mid-July.
In both cases, the expected shortage was due to rising demand, the medicines agency said.
“Novo Nordisk is experiencing a high demand for Wegovy, which can result in periodic backorders of various doses of the product in Denmark,” Novo Nordisk said in a statement to Reuters late on Tuesday.
“In the case of Wegovy FlexTouch 1.0 mg and 0.5 mg, the announcements from the Danish Medicines Agency are no longer current,” it said.
Wegovy is given by weekly injection and belongs to a class of drugs known as GLP-1 agonists originally developed to treat type 2 diabetes.
Weekly Wegovy injections start at 0.25 mg of active ingredient semaglutide and gradually increase to the maintenance dose of 2.4 mg.
Novo, which has been struggling with supply constraints due to run-away demand for the hugely popular drug said all doses were available in Denmark.
(Reporting by Louise Rasmussen and Stine Jacobsen, editing by Terje Solsvik)
Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content.